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Abstract
Background: Recent publications have raised concerns of reduced susceptibilities of clinical bacterial isolates
towards biocides. This study presents a comparative investigation of the susceptibility of livestock-associated
Methicillin-resistant Staphylococcus aureus (LA-MRSA), hospital-acquired MRSA (HA-MRSA) and community-aquired
MRSA (CA-MRSA) to the commonly used antiseptics chlorhexidine (CHX), octenidine (OCT), polyhexanide (PHMB),
PVP-iodine (PVP-I) and triclosan (TCX) based on internationally accepted standards.
Methods: In total, 28 (18 LA-, 5 HA- and 5 CA) genetically characterized MRSA strains representing a broad
spectrum of hosts, clonal complexes and spa-types, as well as the reference methicillin-sensitive Staphylococcus
aureus (MSSA) strain ATCC 6538, were selected. Minimal inhibitory concentration (MIC) and minimal microbicidal
concentration (MBC) were determined in accordance with DIN 58940–7, 58940–8 and DIN EN ISO 20776-1. The
microbicidal efficacy was determined in accordance with DIN EN 1040.
Results: Results from the MIC/MBC and quantitative suspension tests revealed differences between antiseptic
substances but not between epidemiological groups of MRSA strains. OCT and PHMB were the most active
substances with a minimal MIC of 1 mg/L, followed by CHX (2 mg/L), TCX (32 mg/L) and finally PVP-I (1024 mg/L).
The MSSA reference strain showed a tendency to a higher susceptibility compared to the MRSA strains.
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Conclusions: This investigation of the susceptibility of a range of LA-, HA- and CA-MRSA strains using standardized
conditions gave no indication that LA-MRSA strains are less susceptible to commonly used antiseptics compared to
HA- and CA-MRSA strains.
Keywords: MRSA, Resistance, Decolonization, Antisepsis
Background
Antiseptic agents such as chlorhexidine digluconate (chlor-
hexidine, CHX), octenidine dihydrochloride (OCT), poly-
hexanide (polyhexamethylene biguanide, PHMB), PVP-
iodine (Poly(vinylpyrrolidone)-iodine complex, PVP-I), and
triclosan (5-chlorine-2-(2,4-dichlorphenoxy)-phenol, TCX)
are widely used as topical antiseptics against colonization
and infection of humans and animals with Methicillin-
resistant Staphylococcus aureus (MRSA) [1–7]. The clinical
benefits of decolonization of MRSA patients for prevention
of nosocomial infections is well documented [8–10]. The
antimicrobial properties of these agents against hospital
acquired (HA) MRSA strains have been repeatedly shown
[11–17]. However, to our best knowledge, there are no
systematic investigations comparing the susceptibility of
livestock-associated (LA) and community-associated (CA)
strains versus HA-MRSA strains to these antiseptics using
standardized and harmonized test procedures. As CA- and
LA-MRSA strains make up a growing proportion of MRSA
strains in humans [18], such studies are quite pertinent.
Our investigation was to test different antiseptics to se-
lected MRSA strains reflecting stains that are prevalent in
Germany with the main attention on LA-MRSA.
Methods
In order to provide reliable and reproducible informa-
tion on the susceptibility of MRSA strains, the minimal
inhibitory concentration (MIC), the minimal microbici-
dal concentration (MBC) (microdilution test; EN 58940)
as well as the microbicidal efficacy (quantitative suspen-
sion test; EN 1040) of CHX, OCT, PHMB, PVP-I and
TCX were determined in a comparative study under
standardized conditions [19–22] using a spectrum of
genetically characterized strains from different hosts.
Test strains
Strains were drawn from the national collection of the
Robert Koch-Institute (RKI) to represent a broad
spectrum of strains from different hosts that are preva-
lent in Germany, and from a collection of regional
strains from northeastern Germany (HICARE Study)
(Table 1) [23]. Methicillin-sensitive Staphylococcus aur-
eus (MSSA) ATCC 6538 was used as the reference
strain. The reference strain comes from the American
Type Culture Collection (ATCC®), a scientifically recog-
nized source, and has defined resistance properties [24].
The S. aureus Genotyping Kit 2.0 (Alere Technologies
GmbH, Jena, Germany) was used to test selected isolates
for the presence of genes encoding quaternary ammo-
nium compound efflux pumps (qac genes), as described
elsewhere [25]. None of the tested strains in this com-
parison harbored qac genes.
Test preparations
Chlorhexidine digluconate (20% CHX solution, C 9394,
Sigma-Aldrich Biochemie GmbH, Hamburg, Germany),
octenidine dihydrochloride (Schülke & Mayr GmbH,
Norderstedt, Germany), polyhexanide (20% PHMB
solution, Fagron GmbH & Co. KG, Hamburg, Germany)
and PVP-I (Betaisodona solution: 100 ml of the solution
contains 10 g of poly(1-vinyl-2-pyrrolidone-)iodine-
complex, with a content of 11% available iodine, Mundi-
pharma GmbH, Limburg, Germany) and were diluted in
water of standardized hardness (WSH; according to DIN
EN 1040 [19]) to the final test concentrations. As TCX
(Irgasan, 72779, Fluka, Buchs, Switzerland) dissolves
poorly in water, a stock solution of 50% TCX in 80%
dimethylsulfoxide (DMSO) was diluted in several steps
to obtain a final concentration of 1% TCX in 40%
DMSO/WSH. A 40% DMSO/WSH solution was used in
all dilution steps.
The suitability of 40% DMSO in WSH was demon-
strated using the quantitative suspension test and the
microdilution test as described previously [26].
The following solutions were used as neutralizing agents
in accordance with DIN EN 1040 and 1275 [19, 20]:
– 3.0% (w/v) polysorbate 80 + 3.0% (w/v) saponin +
0.1% (w/v) L-histidine + 0.1% (w/v) cysteine for neu-
tralizing CHX, OCT and PHMB
– 3.0% (w/v) polysorbate 80 + 0.3% (w/v) lecithin +
0.3% (w/v) L-histidine + 0.5% (w/v) sodium thiosul-
fate for neutralizing PVP-I
– 8.0% (w/v) polysorbate 80 + 2.0% (w/v) sodium
dodecylsulfate (SDS) + 0.8% (w/v) lecithin + 1.0%
(w/v) sodium thiosulfate + 6.0% (w/v) saponin for
neutralizing TCX.
To determine the MICs and the MBCs, the substances
were prepared in concentrations from 0.25 to 4096mg/L
(Table 2). Concentration ranges used in the quantitative
suspension tests are summarized in Table 2.
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Microdilution test
DIN EN 58940–7 [21] and 58940–8 [22] and the corre-
sponding supplementary sheets were strictly followed to
determine the MIC and MBC, as described previously
[26]. Briefly, the test organisms were cultivated on
CASO agar at 37 °C for 18 h; thereafter, four to five col-
onies were transferred into 1 ml of BBL Mueller Hinton
Broth (BD, Becton Dickinson) and diluted to reach 5 ×
105 cfu/ml. Tests were performed in 96-well microtiter
plates. Each test was performed in duplicate. Each well
was filled with 100 μl of defined antiseptic dilution and
100 μl of test organism suspension. The turbidity was
visually evaluated as an indicator of bacterial growth and
minimal inhibitory concentration after 24 h (MIC24) and
Table 1 List of LA-MRSA, HA-MRSA and CA-MRSA strains with source, spa-type, SCCmec, resistance phenotype and provider
LA-MRSA Source Spa-type SCCmec; other Resistance Phenotype Provider
CC398 pig t034 V PEN, OXA, ERY, CLI, TET, CIPi, SXT, OXA/Su RKI
CC398 cow t011 ND PEN, OXA, TET, OXA/Su RKI
CC398 turkey t034 ND PEN, OXA, ERY, CLI, TET, SXTi, OXA/Su RKI
CC398 poultry t011 ND PEN, OXA, ERY, CLI, TET, SXT, OXA/Su RKI
CC398 horse t011 IV PEN, OXA, GEN, ERY, CLI, TET, CMP, SXT, OXA/Su RKI
CC398 horse t6867 IV PEN, OXA, GEN, TET, COX, OXA/Su RKI
CC398 human t034 V PEN, OXA, TET, SXTi, OXA/Su RKI
CC398 human t899 IV PEN, OXA, OXA/Su RKI
CC398 human t2123 ND PEN, OXA, GEN, TET, CIP, OXA/Su RKI
CC398 human t2370 ND ND HICARE
CC398 human t1456 ND ND HICARE
CC398 human t3275 ND ND HICARE
CC398 human t10721 ND ND HICARE
CC130 deer t843 ND PEN, OXA, OXA/Su RKI
CC130 horse t843 ND PEN, OXA, OXA/Su RKI
CC130 human t1773 ND PEN, OXA, CIPi, OXA/Su RKI
CC9 chicken t1430 ND PEN, OXA, CIP, MFL, OXA/Su RKI
CC9 human t1430 ND PEN, OXA, ERY, CLI, CIP, MFL, OXA/SU RKI
HA-MRSA Source Spa-type SCCmec; other Provider
CC22 human t032 IV PEN, OXA, ERY, CLI, CMP, CIP, MFL, OXA/Su RKI
CC22 human t020 ND PEN, OXA, ERY, CLI, CIP, MFL, OXA/Su RKI
CC22 human t005 ND PEN, OXA, OXA/Su RKI
CC5 (ST225) human t003 II PEN, OXA, ERY, CLI, CMP, CIP, MFL, OXA/Su RKI
CC5 (ST5) human t002 ND PEN, OXA, ERY, CLI, CIP, MFL, OXA/Su RKI
CA-MRSA Source Spa-type SCCmec; other Provider
CC1 human t5100 nd, lukPV, seh PEN, OXA, GEN, TET, FUS, COX, OXA/Su RKI
CC8 human t1476 ND ND HICARE
CC8 human t008 IV, lukPV PEN, OXA, ERY, CIP, MFL, OXA/Su RKI
CC80 human t044 IV, lukPV PEN, OXA, TET, CIP, MUPi, FUS, OXA/Su RKI
CC59 human t437 nd, lukPV PEN, OXA, ERY, CLI, TET, CMP, OXA/Su RKI
RKI Robert Koch-Institute, HICARE HICARE Study, ND not determinded; Groups of strains were defined genetically by spa-typing, MLST, and SCCmec, as well as
demonstration of luk-PV
Table 2 Concentration ranges used for determining MICs and
MBCs in accordance with DIN EN 58940–7 and 58940–8) [18]
and concentration ranges of the test preparations used in the
quantitative suspension tests according to DIN EN 1040 [15]
CHX OCT PHMB PVP-I TCX
Concentration range of Antiseptic agent for MICs and MBCs
determination [mg/L]
0.25–4 0.25–4 0.25–4 256–4096 16–256
Concentration range of Antiseptic agents for quantitative suspension
tests [mg/L]
125–500 20–40 50–100 5,000 – 10,000 250–1,000
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after 48 h (MIC48). To determine the MBC, samples in
the range of the threshold for turbidity after 24 h were
transferred onto blood agar, as described in the stan-
dards, and evaluated for growth after 24 h incubation
(MBK24).
Quantitative suspension test
DIN EN 1040 [19] was strictly applied to determine the
bactericidal efficacy without organic load. Briefly, 0.1 ml
of test organism suspension and 0.1 ml of WSH were
mixed and left for 2 min. Afterwards, 0.8 ml of the re-
spective antiseptic test substance were added. The
resulting solutions were incubated for 5 and 30min at
37 °C. At the end of the contact time, 0.1 ml of the test
solution was transferred to 0.8 ml of the respective neu-
tralizing solution and 0.1 ml WSH and left for 5 min.
Serial dilutions were prepared in neutralizer; 0.1 ml of
each neutralized test dilution was spread onto nutrient
agar plates in duplicates. After incubation for 24 h, the
colonies were counted and the number of recoverable
colonies (Na) in the test solution was calculated. The re-
duction factor (RF) was determined as the difference of
the log number of cells in the test solution at the begin-
ning of the contact time (N0) and log of Na.
In addition to the DIN EN, negative controls using
0.8 ml of WSH instead of test preparation were per-
formed simultaneously in the first test run to exclude
any bactericidal effects of WSH. In the water con-
trols, no essential difference was observed compared
to the N0 values.
Statistics
Data were prepared using Microsoft Excel 2010 (Micro-
soft, Redmond, WA, USA) and analyzed using IBM
SPSS Statistics 24 (IBM, Armonk, NY, USA). Strains
were grouped as LA-, HA- and CA strains.
Robust nonparametric statistics were used to compare
results from the microdilution tests and quantitative
suspension tests [27]. A two-step procedure was chosen
to avoid alpha-error inflation. Kruskal-Wallis tests were
used as omnibus tests for multiple comparisons. If the
omnibus tests indicated statistically significant differ-




Values of MICs and MBCs of tested substances showed
marked differences between LA-, HA- and CA-MRSA
(Table 3). OCT and PHMB were the most active sub-
stances with a minimum MIC of 1 mg/L followed by
CHX, TCX and finally PVP-I. There was no significant
difference between MIC24 and MIC48 of the same
substances between LA-, HA- and CA-MRSA (Related-
Samples-Wilcoxon-Signed-Rank Test, p = 1.00). There
was a significant differences between MBC24 and MIC24
for all substances but TCX (Related-Samples-Wilcoxon-
Signed-Rank-Test, p < 0.01). TCX showed the greatest
range between minimum and maximum MIC and MBC
values.
Values of MIC24, MIC48 and MBC24 differed signifi-
cantly between groups of strains for PHBM (p = 0.003,
Table 3 Rounded means and range of MIC24, MIC48 and MBC LA-, HA- and CA-MRSA strains in mg/L
Stains ATCC_6538
(reference)
LA-MRSA HA-MRSA CA-MRSA Total
Substance and Test Mean Mean Range Mean Range Mean Range Mean Range p-Value
CHX MIC 24 4 2 2–4 3 2–4 3 2–4 3 2–4 0.217
CHX MIC48 4 2 2–4 3 2–4 3 2–4 3 2–4 0.217
CHX MBC24 8 5 4–8 4 4–4 5 4–8 5 4–8 0.173
OCT MIC 24 2 1 1–2 1 1–1 1 1–2 1 1–2 0.153
OCT MIC48 2 1 1–2 1 1–1 1 1–2 1 1–2 0.153
OCT MBC24 4 2 2–4 2 2–2 3 2–4 3 2–4 0.153
PHMB MIC 24 1 2 1–2 2 2–2 2 2–2 2 1–2 0.003
PHMB MIC48 1 2 1–2 2 2–2 2 2–2 2 1–2 0.003
PHMB MBC24 1 4 2–4 4 4–4 4 4–4 4 1–4 0.002
PVP-I MIC 24 1024 1991 1024–4096 2048 2048–2048 2458 2048–4096 2048 1024–4096 0.098
PVP-I MIC48 1024 1991 1024–4096 2048 2048–2048 2458 2048–4096 2048 1024–4096 0.098
PVP-I MBC24 2048 3754 2048–4096 4096 4096–4096 4096 4096–4096 3814 2048–4096 0.053
TCX MIC 24 8 52 32–64 64 64–64 102 64–256 61 8–256 0.020
TCX MIC48 8 52 32–64 64 64–64 102 64–256 61 8–256 0.020
TCX MBC24 8 52 32–64 64 64–64 102 64–256 61 8–256 0.020
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p = 0.003 and p = 0.002) and TCX (all p = 0.02) but not
for CHX (p = 0.217, p = 0.217 and p = 0.173), OCT (all
p = 0.153) and PVP-I (p = 0.098, p = 0.098 and p = 0.053)
in the Independent-Samples Kruskal-Wallis test. Pair-
wise comparison of MIC24, MIC48 and MBC24 of PHMB
showed that this was caused by a higher susceptibility of
the reference MSSA strain compared to the MRSA
strains (p < 0.02). Pairwise comparisons for TCX showed
that HA- and CA-MRSA strains were less susceptible to
TCX than the reference strain (p = 0.021 and 0.01 re-
spectively), and CA-MRSA was significantly less suscep-
tible than LA-MRSA (p = 0.035).
Quantitative suspension test
The archived reduction factors show that all substances
were used at or below the concentration needed to
achieve the threshold set by DIN EN 1040 (at least a 5
log-step reduction) to be adequately bactericidal, as
planned. As expected, reduction factors increased with
contact time and concentration of the antiseptic
(Fig. 1a-e). In contrast, the MSSA reference strain
showed a higher susceptibility to CHX than did the
MRSA strains, but the differences were not statistically
significant in the omnibus test. All other tests for statis-
tical significance were omitted due to the small absolute
differences and the overlapping confidence intervals.
Discussion
The antibacterial activity of common antiseptics against
a broad range of different pathogens has been well docu-
mented [26, 28]. Still, little is known about the differ-
ences in the susceptibility to antiseptics of LA-MRSA in
comparison to HA-MRSA and CA-MRSA. While anti-
septics show a broader antimicrobial spectrum com-
pared to antibiotics and are less compromised by
specific resistances, reduced susceptibility of various
strains to antiseptics has been reported [29–33]. Besides
antimicrobial agents other facts like metal-resistance
genes might contribute to differences the susceptibility
to antiseptics. For example Argudin et al. reported the
occurrence of different metal-resistance genes among
LA-MRSA [31]. Recent publications in particular have
raised concerns of reduced susceptibilities of distinctive
clinical isolates towards biocides and found associations
with outbreaks [29, 33, 34].
Therefore, the susceptibility of LA-MRSA to antisep-
tics is an important issue, as LA-MRSA is an emerging
problem and antiseptic agents are valuable drugs for
prevention of MRSA infections [18, 35]. For example,
antiseptic decolonization has been proven to control the
spread of MRSA in intensive care healthcare settings [8]
and to reduce surgical site infections [36]. Neverthe-
less, the effectiveness of these measures relies on the
susceptibility of the targeted pathogens to the antisep-
tic products used.
Other mechanisms for reduced susceptibility to disin-
fectants in MRSA besides the qac gene coded efflux
pumps have been described: reduced susceptibility to
chlorhexidine can also result from mutations in the
norA/norB genes which code for an efflux mechanism
[29]. Reduced susceptibility to triclosan can be due to
either enhanced expression of the target of this biocide,
namely the enoyl-acyl carrier protein (ACP) reductase
enzyme (FabI) [37], or acquisition of an additional sh-
fabI allele derived from Staphylococcus haemolyticus by
horizental gene transfer [27]. We found no evidence of
reduced susceptibility of LA-MRSA to CHX, OCT,
PHMB, PVP-I and TCX in comparison to CA- and HA-
MRSA. Differences in the susceptibility between the
strains in MIC, MBC and microdilution assays were
marginal. With a difference not greater than one dilution
step, the range between the highest and lowest MIC and
MBC between the groups of MRSA stains was at the
same level or even smaller, as between the strains of the
same group (one step for CHX, PHMB and OCT and up
to two steps for PVP-I and TCX). The only exception
was TCX in terms of LA-MRSA strains, which were
significantly more susceptible than CA-MRSA.
Likewise, the results from the quantitative suspension
assays were quite comparable between CA-, HA- and
CA-MRSA strains. In contrast, the reference MSSA
strain showed a tendency to higher susceptibility in the
MIC, MBC and quantitative suspension assays. However,
as only one reference strain was used, it is unclear
whether this can be interpreted as higher susceptibility
of MSSA in contrast to MRSA or as an attribute of the
specific strain.
Our results are well comparable with those of other
published studies. MICs reported by Koburger et al. for
aureus ATCC 6538 almost matched our results, with the
exception of PVP-I and TCX, which showed a markedly
higher MIC48 and MBC24 in our tests [26]. The differ-
ences for PVP-I remain unexplained, while the reported
higher MICs to TCX in comparison to Koburger et al.
(0.125 versus 8 mg/L) can be explained by the fact that
8 mg/L was the lowest concentration used in our tests.
Furthermore, the tested MRSA-strain, a northern
German epidemic strain, showed susceptibilities com-
parable to our results. Likewise, MICs to PHMB and
TXC reported by Assadian et al. for MRSA, low level
vancomycin-resistant (VISA) S. aureus strains and S.
aureus ATCC 29213 correspond well to our results [11].
Interestingly, the MSSA reference strains showed a ten-
dency to higher susceptibility to TCX in this two studies
compared to MRSA.
It is important to bear in mind that the concentrations
used in our study were well below the concentrations
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Fig. 1 (See legend on next page.)
Dittmann et al. Antimicrobial Resistance and Infection Control           (2019) 8:122 Page 6 of 9
recommended by the manufacturer. For example, PHMB
is used at a concentration of 0.02% or 200mg/L, which
is 200 times greater than the MIC24 for wound
antisepsis.
The strength of the present study is the systematic ap-
proach based both on European standards for assessing
the bactericidal effects in quantitative suspension assays
and on industry standards to determine the MIC and
MBC using the microdilution method [19, 21, 22, 26].
Our method can therefore easily be replicated by other
researchers and for other strains. One point worthy of
note is that parts of DIN 58940 have since been sus-
pended and replaced by DIN EN ISO 20776-1:2007–02.
However, this has no effects in terms of determining the
MIC and MBC for antiseptics in this study.
Our study has limitations. For instances, we used only
a limited number of strains and antiseptics for our ana-
lysis. It is well known that some strains express higher
resistances to specific antiseptics. Resistance to antisep-
tics can arise through different mechanisms [38]. For
example, efflux-mediated resistance to various biocides
linked to qac-genes has been reported in different
staphylococcal isolates in recent years [39–41]. However,
this does not detract from our research question of
whether LA-strains show a higher resistance to antisep-
tics compared to HA- and CA strains per se, as qac-
genes have been reported in HA-, CA- and LA-strains
alike. Although we used a limited number of strains, all
were genetically characterized and represented a broad
spectrum of hosts, clonal complexes and spa-types. Most
strains were drawn from the national collection of the
Robert Koch Institute and were supplemented by re-
gional strains from northeastern Germany as well as an
ATCC reference strain. The aim of our study was to
evaluate the susceptibility of LA-MRSA to different anti-
septics in comparison to HA-MRSA and CA-MRSA.
The MSSA reference strain serves as an intern control.
The shown difference between the reference and the test
strains should not be interpreted as evidence for a higher
susceptibility of MSSA to MRSA strains in general.
Regarding the limited number of antiseptics used, we
covered a broad spectrum of substances with different
modes of action. Our selection included CHX, probably the
most commonly used antiseptic agent worldwide, and
OCT, PHMB, PVP-I and TCX. These substances are widely
used in specific fields of application, such as antisepsis on
skin and mucous membranes [1, 4], the eye [42, 43], acute
and chronic wounds [2, 6] and sutures [44].
In summary, the present study gives no reason to
doubt that the tested antiseptics can kill LA-MRSA at
the concentrations recommended for use by the manu-
facturer. However, if the substances are diluted, which
can happen deliberately as result of the usage (e.g., when
irrigating wounds) or as part of the intended application
(e.g., slow release of CHX from patches or TCX from
sutures), the concentration may be reduced to levels that
fall short of the MIC. As recent publications raise con-
cerns about the increasing resistance of clinical isolates
to antiseptics and disinfectants, this highlights the im-
portance of safe and conscientious use of antiseptics.
Conclusion
This investigation of the susceptibility of a broad range
of HA-, LA- and CA-MRSA strains using standardized
and harmonized conditions provided no indication
that LA-MRSA strains show reduced susceptibility to
commonly used antiseptics compared to HA- and
CA-MRSA strains.
(See figure on previous page.)
Fig. 1 a Results of quantitative suspension test for chlorhexidine for LA-MRSA, HA-MRSA, CA-MRSA and reference MSSA. Different concentrations
of chlorhexidine (CHX; 125 mg/L, 250 mg/L and 500mg/L) were suspended to different MRSA strains and the MSSA reference strain at two
different contact times (5 min and 30min). LA-MRSA (beige), HA-MRSA (green), CA-MRSA (blue) and reference MSSA (purple). Error bars show
95% confidence intervals. Horizontal line at the value of the mean reduction factor of 5 indicates bactericidal threshold according to DIN EN
1040. b Results of quantitative suspension test for octinidine for LA-MRSA, HA-MRSA, CA-MRSA and reference MSSA. Different concentrations of
octinidine (OCT; 50 mg/L, 75 mg/L and 100mg/L) were suspended to different MRSA strains and the MSSA reference strain at two different
contact times (5 min and 30min). LA-MRSA (beige), HA-MRSA (green), CA-MRSA (blue) and reference MSSA (purple). Error bars show 95%
confidence intervals. Horizontal line at the value of the mean reduction factor of 5 indicates bactericidal threshold according to DIN EN 1040.
c Results of quantitative suspension test for polyhexanide for LA-MRSA, HA-MRSA, CA-MRSA and reference MSSA. Different concentrations of
polyhexanide (PHMB; 5000 mg/L, 7500 mg/L and 10000mg/L) were suspended to different MRSA strains and the MSSA reference strain at two
different contact times (5 min and 30min). LA-MRSA (beige), HA-MRSA (green), CA-MRSA (blue) and reference MSSA (purple). Error bars show
95% confidence intervals. Horizontal line at the value of the mean reduction factor of 5 indicates bactericidal threshold according to DIN EN
1040. d Results of quantitative suspension test for PVP-iodine for LA-MRSA, HA-MRSA, CA-MRSA and reference MSSA. Different concentrations of
PVP-iodine (PVP-I; 20 mg/L, 30 mg/L and 40 mg/L) were suspended to different MRSA strains and the MSSA reference strain at two different
contact times (5 min and 30min). LA-MRSA (beige), HA-MRSA (green), CA-MRSA (blue) and reference MSSA (purple). Error bars show 95%
confidence intervals. Horizontal line at the value of the mean reduction factor of 5 indicates bactericidal threshold according to DIN EN 1040.
e Results of quantitative suspension test for triclosan for LA-MRSA, HA-MRSA, CA-MRSA and reference MSSA. Different concentrations of triclosan
(TCX; 250 mg/L, 500 mg/L and 1000 mg/L) were suspended to different MRSA strains and the MSSA reference strain at two different contact times
(5 min and 30min). LA-MRSA (beige), HA-MRSA (green), CA-MRSA (blue) and reference MSSA (purple). Error bars show 95% confidence intervals.
Horizontal line at the value of the mean reduction factor of 5 indicates bactericidal threshold according to DIN EN 1040
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Abbrevations
CA-MRSA: Community-aquired Methicillin-resistant Staphylococcus aureus;
CHX: Chlorhexidine; HA-MRSA: Hospital-acquired Methicillin-resistant
Staphylococcus aureus; LA-MRSA: Livestock-associated Methicillin-resistant
Staphylococcus aureus; MBC: Minimal microbicidal concentration;
MIC: Minimal inhibitory concentration; MRSA: Methicillin-resistant
Staphylococcus aureus; MSSA: Methicillin-sensitive Staphylococcus aureus;
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